Towards patient-specific prediction of conduction abnormalities induced by transcatheter aortic valve implantation: a combined mechanistic modelling and machine learning approach

Valeria Galli 1*,†, Filip Loncaric 2†, Giorgia Rocatello 1, Patricio Astudillo 1, Laura Sanchis 3, Ander Regueiro 3, Ole De Backer 4, Martin Swaans 5, Johan Bosmans 6, Joana Maria Ribeiro 7, Pablo Lamata 8, Marta Sitges 2,3,9, Peter de Jaegere 7, and Peter Mortier 1*

1FEops NV, Technologiepark 122, 9052 Ghent, Belgium; 2Institute of Biomedical Research August Pi Sunyer (IDIBAPS), Carrer del Rosselló, 149, 08036, Barcelona, Spain; 3Cardiovascular Institute, Hospital Clinic and Universitat de Barcelona, C. de Villarroel,170, 08036 Barcelona, Spain; 4Department of Cardiology, Rigshospitalet University Hospital, Blegdamsvej 9, 2100 Copenhagen, Denmark; 5Department of Cardiology, St. Antonius Ziekenhuis, Koekoekslaan 1, 3435 CM Nieuwegein, The Netherlands; 6Department of Cardiology, University Hospital Antwerp, Drie Eikenlaan 655, 2650 Edegem, Antwerp, Belgium; 7Department of Cardiology, Erasmus MC, Doctor Molewaterplein 40, 3015 GD Rotterdam, The Netherlands; 8Department of Biomedical Engineering, King’s College London, Strand, London WC2R 2LS, UK; and 9Centro de Investigación Biomédica en Red de Enfermedades Cardiovasculares (CIBERCV), Instituto de Salud Carlos III, Av. Monforte de Lemos, 3-5, Pabellón 11, Planta 0 28029 Madrid, Spain

Received 10 March 2021; revised 12 May 2021 online publish-ahead-of-print 20 August 2021

Aims

Pre-procedure conduction abnormalities (CA) remain a common complication of transcatheter aortic valve implantation (TAVI), highlighting the need for personalized prediction models. We used machine learning (ML), integrating statistical and mechanistic modelling to provide a patient-specific estimation of the probability of developing CA after TAVI.

Methods and results

The cohort consisted of 151 patients with normal conduction and no pacemaker at baseline who underwent TAVI in nine European centres. Devices included CoreValve, Evolut R, Evolut PRO, and Lotus. Preoperative multi-slice computed tomography was performed. Virtual valve implantation with patient-specific computer modelling and simulation (CM&S) allowed calculation of valve-induced contact pressure on the anatomy. The primary composite outcome was new onset left or right bundle branch block or permanent pacemaker implantation (PPI) before discharge. A supervised ML approach was applied with eight models predicting CA based on anatomical, procedural and mechanistic data. CA occurred in 59% of patients (n=89), more often after mechanical than first or second generation self-expanding valves (68% vs. 60% vs. 41%). CM&S revealed significantly higher contact pressure and contact pressure index in patients with CA. The best model achieved 83% accuracy (area under the curve 0.84) and sensitivity, specificity, positive predictive value, negative predictive value, and F1-score of 100%, 62%, 76%, 100%, and 82%.

Conclusion

ML, integrating statistical and mechanistic modelling, achieved an accurate prediction of CA after TAVI. This study demonstrates the potential of a synergetic approach for personalizing procedure planning, allowing selection of the optimal device and implantation strategy, avoiding new CA and/or PPI.

*Corresponding authors. Tel: +32 348013684, Email: valeria_galli@outlook.com (V.G.); Tel: +32 474274543, Email: peter.mortier@feops.com (P.M.)
†contributed equally

© The Author(s) 2021. Published by Oxford University Press on behalf of the European Society of Cardiology. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.
**Introduction**

Transcatheter aortic valve implantation (TAVI) benefits patients with aortic stenosis at high, intermediate, and low surgical risk. Notwithstanding continuous improvements in outcomes due to advancement in catheter and valve technologies, as well as increase in experience, the occurrence of new conduction abnormalities (CA) and, consequently, new permanent pacemaker implantation (PPI) remains a clinical problem. The occurrence of new onset left bundle branch block with first generation valves was reported to vary between 4% and 65%. Acknowledging institution-dependent variables affecting PPI, an incidence varying between 2% and 51% was observed in a meta-analysis of 41 studies. Patient, procedure/operator, and device related factors have been shown to help estimate the risk of a new CA after TAVI on a population level, but the contribution of each factor in the individual patient remains unknown, highlighting the need for a more personalized approach in routine planning.

Artificial intelligence is increasingly used to enhance the quality and efficacy of the planning, execution and evaluation of complex cardiac interventions such as TAVI. In parallel, developments in mechanistic models allows the addition of physiology and physics for a more profound identification of the mechanisms of cardiac disease and complications following medical interventions. Recently, the synergy between statistical and mechanistic models, combining inductive and deductive reasoning, has been suggested for the realization of precision medicine—more accurate diagnosis, treatment decision-making and, hence, prognosis. In this context, the entanglement of the mechanisms leading to CA after TAVI presents an appropriate challenge for such a tailored approach (Figure 1). The aim of this study was to develop and evaluate a patient-specific model predicting new CA after TAVI using machine learning (ML), combining statistical and mechanistic modelling.

**Methods**

**Patient cohort**

The retrospective index cohort consisted of 189 patients who had undergone TAVI in nine European centres. Patients with abnormal ECG [left/right bundle branch block (L/RBBB)] and/or permanent pacemaker before TAVI (n = 38) were excluded. Therefore, the final study cohort included 151 patients who were treated with the self-expanding CoreValve, Evolut R, and Evolut PRO valves (n = 107, Medtronic, MN, USA), or the mechanically expanding Lotus valve (n = 44, Boston Scientific, MA, USA). All patients were discussed in the multidisciplinary heart team. Valve type selection was based upon discretion of the operator/institution, whereas valve sizing was based upon multi-slice computed tomography (MSCT) derived baseline aortic root anatomy using the manufacturing sizing matrix, as described before. The primary and dependent outcome of interest was the occurrence of a new L/RBBB and/or PPI before discharge. All patients provided written informed consent for TAVI and the use of anonymous clinical, procedural, and follow-up data for research. The study was executed according to the...
Declaration of Helsinki, was approved by the ethics committees of all participating centres and did not fall under the scope of the Medical Research Involving Human Subjects Act.

Anatomical measurements and patient-specific mechanistic modelling

Preoperative MSCT was used for procedure planning and simulation. In-plane and through-plane resolution ranged from 0.31 to 0.97 mm/pixel, slice increment from 0.25 to 0.8 mm, and slice thickness from 0.5 to 1.5 mm. For the purpose of simulation, the MSCT of every patient was assessed and analysed by an independent simulation expert (FEops, Gent, Belgium). Some patients were excluded based on the following criteria of MSCT image quality: insufficient contrast, substantial movement in the aortic root and streaking artefacts, low planar scanning resolution, MSCT slice thickness higher than 1.5 mm, or slice increment higher than 0.9 mm. Furthermore, for this specific study, it was necessary to identify the membranous septum, thus patients whose images did not allow it were excluded. Quantification of the base of the aortic root (i.e. annulus and left ventricular outflow tract) including the inferior border of the membranous septum (IBMS) length, IBMS angulation with respect to the annular plane, and the shortest distance of the membranous septum (P3) to the annular plane were performed as previously described (Figure 2A and ref.12) The valve sizing index was calculated as the ratio between the nominal device diameter and the perimeter-derived annular diameter.

Statistical modelling and machine learning

Anatomical (n = 3; IBMS length, IBMS angulation, and the distance of P3 to the annular plane), procedural (n = 3; device type, sizing index, DOI), and mechanistic variables (n = 2; Cmax, CPI) were included as the ML input. The analysis was conducted using the scikit-learn package (v 0.20.4) for Python. A scheme illustrating the central ML methodology is shown in Figure 3.

A preliminary exploratory data analysis was performed to investigate variable distributions (Supplementary material online, Figure 15).
Categorical variables (e.g., device type) were one-hot encoded and numerical ones were normalized to a 0 to 1 scale as is common practice when data presents different value ranges. Additionally, feature (i.e., variable) selection was performed to search for highly correlated uninformative features; in this case, none of the eight features were correlated to another significantly and all were retained. After preprocessing, a supervised learning approach was applied: the cohort was split into training and validation sets (70–30%)—taking into account the distribution of categorical variables, that is, ensuring the presence of samples for each of the three devices in both sets. The training set was used to train the base classifiers (i.e., single classification algorithms) with five-fold cross-validation. We chose algorithms typically used for supervised binary classification, whose technical concepts have been described elsewhere14,15: (i) K-Nearest Neighbour Classifier, (ii) Logistic Regression, (iii) C-Support Vector Classification, (iv) Gaussian Naïve-Bayes, (v) Support Vector Machine with Stochastic Gradient Descent (SGD) learning, (vi) Extreme

**Figure 2** Identification of anatomical landmarks and mechanistic modelling workflow. (A) Identification of the inferior border of the membranous septum (IBMS) using preoperative MSCT images. P1 and P3 are landmarks selected at the beginning and end of the IBMS (white arrows), whereas P2 is an additional point in between to better track the course of the IBMS. The length of IBMS is calculated as the distance from P1 to P3. The angle between the segment connecting P1 and P3 and the annular plane is marked with α. The distance of P3 from the annular plane is marked with D3. (B) The region of interest for contact pressure analysis is defined by the area between the IBMS (extended towards the RCC by a 25° angle12) and the plane 15 mm below the annular level, to ensure inclusion of the proximal part of the left bundle branch. (C) A scheme showing the workflow of mechanistic modelling. A valve with known frame dimensions and mechanical properties is selected and virtually implanted into the patient-specific aortic root anatomy reconstructed from MSCT images. The device-host interactions are assessed—including aortic wall deformation and the resulting contact pressure exerted by the frame on the surrounding anatomy. The figure is based on ref.12 MSCT, multi-slice computed tomography; NCC, non-coronary cusp; RCC, right coronary cusp.
Gradient Boosting Classifier, (vii) Decision Tree Classifier, and (viii) Random Forest Classifier. The trained base classifiers were then combined homogeneously (i.e. bootstrap aggregation) or in a mixed fashion (i.e. voting) and subsequently tested on the validation set. A more detailed explanation of the two ensembling techniques is available in the Supplementary material online. The optimal model was chosen based on accuracy and receiver operator characteristics (ROC) curves were considered with the corresponding area under the curve (AUC). On top of the usual statistics considered [sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV)], F1-score (harmonic mean of PPV and sensitivity) was taken into account as an indication of overall performance of the model.

To determine the importance of mechanistic variables in the prediction of CA, we evaluated their influence by testing the predictive power excluding Cpmax and CPI, as compared to the full model. Furthermore, using all variables, we assessed the performance for predicting L/RBBB only in a sub-cohort (n = 119), excluding patients who received a PPI after TAVI; in this case, the models were re-trained and the most accurate was selected.

Statistics and outcome analysis
Continuous variables are expressed as mean ± standard deviation or median and interquartile range based on their distribution evaluated by the Shapiro–Wilk test. The categorical variables are expressed as number and percentage. Valve technology was differentiated into three categories: CoreValve, Evolut R/PRO, and Lotus—the former two being self-expanding and the latter mechanically expanding. Differences between groups were analysed for statistical significance with the Student’s t-test when comparing variables with normal distribution and the Mann–Whitney test for non-normally distributed variables. Contingency tables and a Chi-square test or Fisher’s exact test were used for categorical data.

Results
Cohort characteristics and patient-specific simulation results
Anatomical and procedural details are summarized in Table 1. The majority of patients received the first generation self-expanding CoreValve (55%), 16% received the second generation Evolut R/PRO. The mechanically expanding Lotus valve was used in 29%. A total of 89 patients (59%) developed new CA after TAVI, which was more frequent after mechanical (30/44, 68%) than after the first (50/83, 60%) or second generation (9/24, 37%) self-expanding valve implantation. Computer modelling and simulation (CM&S) revealed a
Table 1  Characteristics of the population

| Parameter                      | All patients (n = 151) | CA, N = 89 (59%) | No CA, N = 62 (41%) | P-value |
|--------------------------------|------------------------|------------------|---------------------|---------|
| **Anatomical**                 |                        |                  |                     |         |
| Annular diameter, a, mm        | 24.06 ± 2.04           | 24.39 ± 2.10     | 23.60 ± 1.87        | 0.018   |
| IBMS length, mm                | 10.07 ± 3.38           | 10.06 ± 3.64     | 10.09 ± 2.98        | 0.947   |
| IBMS angle (α), °              | 19.55 ± 17.80          | 21.67 ± 16.91    | 16.50 ± 18.74       | 0.079   |
| Depth of P3 (D3), mm           | -2.10 ± 2.27           | -1.87 ± 2.30     | -2.44 ± 2.20        | 0.126   |
| **Pre-procedural**             |                        |                  |                     |         |
| Depth of implantation (DOI), b | 6.26 ± 4.13            | 7.30 ± 3.91      | 4.79 ± 4.02         | <0.001  |
| **Device type**                |                        |                  |                     | 0.047   |
| CoreValve (CV)                 | 83 (55)                | 50 (56)          | 33 (53)             |         |
| Evolut R/PRO (ER/EPRO)         | 24 (16)                | 9 (10)           | 15 (24)             |         |
| Lotus (LT)                     | 44 (29)                | 30 (34)          | 14 (23)             |         |
| **Device size**                |                        |                  |                     | 0.462   |
| CV 26                          | 29 (20)                | 17 (20)          | 12 (21)             |         |
| CV 29                          | 48 (32)                | 28 (31)          | 20 (32)             |         |
| CV 31                          | 6 (4)                  | 5 (6)            | 1 (2)               |         |
| ER/EPRO 26                     | 9 (6)                  | 2 (2)            | 7 (11)              |         |
| ER/EPRO 29                     | 15 (8)                 | 7 (4)            | 8 (13)              |         |
| LT 23                          | 11 (7)                 | 5 (6)            | 6 (10)              |         |
| LT 25                          | 18 (12)                | 12 (13)          | 6 (10)              |         |
| LT 27                          | 15 (10)                | 13 (15)          | 2 (3)               |         |
| Sizing index c                 | 1.14 ± 0.10            | 1.12 ± 0.09      | 1.15 ± 0.10         | 0.081   |
| **Post-procedural**            |                        |                  |                     |         |
| RBBB                           | 1 (0)                  | 1 (1)            | 0 (0)               |         |
| LBBB                           | 78 (52)                | 78 (88)          | 0 (0)               |         |
| PPI                            | 32 (21)                | 32 (36)          | 0 (0)               |         |

Values are given as mean ± standard deviation or n (%). Percentages refer to the total reported in the first row (e.g. N = 89 for the CA column).

IBMS, inferior border of membranous septum; LBBB, left bundle branch block; RBBB, right bundle branch block.

aPerimeter-based diameter = annular perimeter/x.

bImplantation depth assessed in postoperative angiograms: distance from the aortic annular plane on the NCC side to the deepest level of the most proximal edge of the device frame (NCC: non coronary cusp).

cNominal device diameter/annular diameter.

Figure 4 Results of the simulations stratified by occurrence of conduction abnormalities. Boxplots of maximum contact pressure (left) and contact pressure index (right). Numerical values are reported in Table 2.
significantly higher Cpm (about two-fold median value) and CPI (about three-fold median value) in patients with new CA as compared to patients without (Figure 4, Table 2).

**Machine learning for prediction of conduction abnormalities**

The ensemble models were compared based on accuracy score: the homogeneous ensemble (bootstrap aggregation) of K-Nearest Neighbour showed the best performance with 83% accuracy and sensitivity, specificity, PPV, NPV, F1-score, and AUC of 100%, 62%, 76%, 100%, and 82% and 0.84, respectively (Table 3). The ROC curves of the four most accurate models are shown in Figure 5.

A sharp decrease in accuracy was observed when excluding Cpm and CPI as features, with the best ensemble (Support Vector Machine + SGD) having 67% accuracy and 0.72 AUC. The results for this sub analysis are reported in Supplementary material online, Table 15.

The analysis of the prediction of only L/RBBB in the sub-cohort of patients of 119 who underwent TAVI and did not receive a new PPI after TAVI, revealed the highest accuracy when using the Support Vector Machine + SGD (75% with 0.77 AUC—Supplementary material online, Table 25).

An overview of all the analyses and related performance is reported in Supplementary material online, Figure 2S.

**Discussion**

In this multicentric study, we demonstrate the synergy of statistical and mechanistic modelling in predicting new CA after TAVI. The independent variables derived from patient-specific mechanistic modelling, reflecting the interaction between device and host (i.e. contact pressure), were highly predictive of CA. Also, ML-based statistical modelling helped to enhance the predictive ability through the integration of these mechanistic markers with the traditional patient and procedure-related predictive variables. Noteworthy, the prediction ability of the herein proposed model was not only true for the composite of new L/RBBB and new PPI (primary objective of study) but also for new L/RBBB as single endpoint.

The findings of this study need to be interpreted in the light of sample size, patient demographics and valve technology. The cohort of 151 patients was predominantly treated with the first generation self-expanding (55%) or the recently withdrawn mechanical expanding valve (29%). Yet, it goes without saying that the proposed model can in principle be applied to any valve technology. New CA (i.e. L/RBBB and new PPI) occurred in 89 out of the 151 patients (59%). The frequency of new CA after the implantation of the first generation self-expanding CoreValve and the mechanically expanding Lotus valve is in accordance with previously reported clinical observations.8,12,16 This also holds for the Evolut platform of which the Evolut R and Evolut PRO only differ in sealing skirt (affecting paravalvular leak) but not in design and mechanical behaviour.17,18

ML-based prediction of new CA and/or PPI is subject to recent research with varying degrees of performance. Gomes et al reported an AUC of 0.61 for ML-based prediction of new PPI after TAVI.19 Similarly, low accuracy of PPI prediction was seen in a gradient boosting model incorporating baseline ECG, device-related and imaging variables (AUC 0.88). Reasons for disparity in performance in this field of ML-based prediction modelling are multifold. A high-quality dataset consisting of sufficient heterogeneous/multidimensional data as well as the selection of relevant variables are important for model performance. Nevertheless, the generation of novel variables, such as mechanistic ones—as shown in this study—may enhance the predictive power, reduce the number of variables needed and thus increase clinical applicability.

| Model                      | Accuracy | Sensitivity | Specificity | PPV   | NPV   | F1-score | AUC (95% CI) |
|----------------------------|----------|-------------|-------------|-------|-------|----------|--------------|
| K-Nearest Neighbours       | 83%      | 1.00        | 0.62        | 0.76  | 1.00  | 0.82     | 0.84 (0.69–0.95) |
| Logistic Regression        | 80%      | 0.96        | 0.62        | 0.75  | 0.93  | 0.83     | 0.80 (0.70–0.96) |
| Support Vector Machine + SGD | 78%    | 1.00        | 0.52        | 0.71  | 1.00  | 0.83     | 0.81 (0.69–0.95) |
| Gaussian Naive-Bayes       | 76%      | 0.84        | 0.67        | 0.75  | 0.78  | 0.82     | 0.77 (0.69–0.95) |

AUC, area under curve; NPV, negative predictive value; PPV, positive predictive value.

---

**Table 2  Computer modelling and simulation results**

| Parameter                          | All patients (n = 151) | CA, n = 89 (59%) | No CA, n = 62 (41%) | P-value |
|------------------------------------|------------------------|------------------|---------------------|---------|
| Maximum contact pressure (MPa)     | 0.45 (0.26–0.67)       | 0.55 (0.41–0.79) | 0.30 (0.06–0.56)    | <0.001  |
| Contact pressure index (%)         | 22 (8–37)              | 28 (18–44)       | 10 (1–26)           | <0.001  |

Values are given as median (interquartile range).
Predicting conduction abnormalities through the synergy of statistical and mechanistic modelling

Patient-specific CM&S allows the assessment of the interaction between the device and host, generating mechanistic variables that incorporate all the factors playing a role in the injury to the conduction tissue—such as calcifications, sizing, etc. These variables have shown to be predictive of new CA after TAVI. It is clear that the addition of mechanistic parameters to the model comes with the computational cost, but also increases accuracy. In fact, excluding those from the primary model, the predictive power decreased (Supplementary material online, Table 1).

Statistical modelling, through ML or traditional statistical classification algorithms, can improve the prediction of mechanistic variables by combining those with other, traditionally available parameters. In classification tasks such as prediction of adverse events, the selection of tools used in traditional statistical modelling is expanded by ML algorithms, enabling to find the optimal model for the dataset at hand. In our study, predictors of CA were: descriptors of the aortic valve and ascending aorta (i.e. the shortest distance of the membranous septum to the annular plane (P3), length and angulation of IBMS (length of IBMS was previously observed as strong predictor of atrioventricular block and PPI), procedure-related parameters (i.e. valve type, size and DOI), and mechanical properties of the implanted device. The added value of ML integration enhances the observed predictive power based on mechanistic variables only, where statistical univariate and multivariate analyses on subsets of our cohort revealed accuracy of 76% and 77% for CPmax and CPI in CoreValve and Evolut R valves, and analogously 75% and 71% in a subset with Lotus valve alone.

We believe that the synergy between statistical and mechanistic modelling helps the development of patient-tailored, personalized or precision medicine. Clinicians are becoming gradually familiar with ML-based approaches, yet, mechanistic modelling is still a niche concept in clinical medicine. Mechanistic models allow the extraction and combination of patient-specific biomarkers that stem from computer simulations such as herein reported (i.e. patient-specific interaction of valve with MSCT derived anatomy). The value of such a combined approach has—among others—been demonstrated in cardiac resynchronization therapy and hypertrophic cardiomyopathy. In case of aortic valve disease, such an approach can be applied prospectively in order to provide a tailored prediction of adverse events and, thus, improve patient selection, procedure planning and execution by modelling all relevant parameters before the procedure (device type and size as well as DOI).

Limitations

The presented model stems from a medium-sized cohort from nine European centres. The number of variables included in the analysis is limited by the retrievability of data. Information on demographics, comorbidities, baseline clinical variables, and echocardiograms was not available for the complete cohort and were, therefore, not used as additional (candidate) predictors in the modelling. Similarly, the exact timing of L/RBBB insurgence or PPI—periprocedurally or after discharge—was not available. On the other hand, data from MSCT imaging, with detailed anatomical descriptors of the aortic valve and ascending aorta, was paired with case-specific mechanistic modelling. Validation of the model using an external data set has not been performed.

The composite outcome of L/RBBB and PPI is hindered by the variability in clinical decision-making of PPI between and within centres. Therefore, we performed an additional analysis to predict the outcome of L/RBBB as the only independent outcome-measure in the sub-cohort of patients who underwent TAVI free from new PPI after procedure, showing slightly lower accuracy when applying this more robust endpoint.

As far as the computational modelling is concerned, although it would be more appropriate to consider distributions of the mechanistic parameters at varying implantation depths and device rotation, this would be computationally too expensive, especially in the perspective of a larger dataset.

In order to confirm the generalizability of our findings, a more comprehensive dataset featuring additional parameters such as age, gender, body surface area, and other common clinical variables will be needed.

Lastly and as mentioned above, most patients were treated with the first generation CoreValve and the recently withdrawn mechanical-expanding Lotus valve. Few patients were treated with currently used self-expanding valves. Balloon-expandable valves were not included. Yet, the model herein proposed does not depend on the valve technology itself but can be applied to any commercial device.

Conclusions

Combining statistical and mechanistic modelling helps the development of patient-specific prediction of adverse events after TAVI. Through data integration with traditional predictors of CA, ML-based classification models enhance the predictive ability of patient-specific mechanistic modelling. We believe that application of the presented method applied on prospective patients in the future may help the physician to select the device that best fits the individual patient and implantation strategy.
Valeria Galli holds a Master of Science (summa cum laude) in Biomedical Engineering obtained at Politecnico di Milano. She currently works as R&D engineer at FEops nv (Gent, Belgium) while being Early-Stage Researcher in the EU H2020 project ‘Personalised In-Silico Cardiology’. She is active in the field of patient-specific computer simulations for structural heart interventions (finite element analysis and computational fluid dynamics). Her interests include the application of artificial intelligence methods for prediction of procedural outcome, automated image segmentation, and landmarks detection.

Supplementary material

Supplementary material is available at European Heart Journal – Digital Health online.

Consent: All patients provided written informed consent for TAVI and the use of anonymous clinical, procedural, and follow-up data for research.

Funding

This work was supported by Horizon 2020 European Commission Project H2020-MSCA-ITN-2016 (764738). P.L. holds a Wellcome Trust Research Fellowship (200945/Z/17/Z).

Conflict of interest: V.G., G.R., and P.A. are employees of Feops. P.M. is shareholder of FEops. All other co-authors declared that they have no conflict of interest. Given his role as deputy editor, P.d.J. had no involvement in the peer review of this article and has no access to information regarding its peer review. Full responsibility for the editorial process for this article was delegated to Joost Lumens.

Data availability

The data underlying this article cannot be shared publicly due to the privacy of individuals that participated in the study and for reasons of intellectual property.

References

1. Leon MB, Smith CR, Mack M, Miller DC, Moses JW, Svensson LG, Tuzcu EM, Webb JG, Fontana GP, Makkar RR, Brown DL, Block PC, Guyton RA, Pichard AD, Bavaria JE, Herrmann HC, Douglas PS, Petersen JL, Akin JJ, Anderson WN, Wang D, Pocock S; PARTNER Trial Investigators. Transcatheter aortic-valve implantation for aortic stenosis in patients who cannot undergo surgery. N Engl J Med 2010;363:1597–1607.
2. Smith CR, Leon MB, Mack MJ, Miller DC, Moses JW, Svensson LG, Tuzcu EM, Webb JG, Fontana GP, Makkar RR, Williams M, Dewey T, Kapadia S, Babalaros V, Tchervenkov I, Goldstein J, Serruys PW. Transcatheter aortic-valve replacement with a balloon-expandable valve in low-risk patients. N Engl J Med 2011;365:1609–1620.
3. Leon MB, Smith CR, Mack MJ, Makkar RR, Svensson LG, Kodali SK, Thourani VH, Tuzcu EM, Miller DC, Herrmann HC, Doshi D, Cohen DJ, Pichard AD, Kapadia S, Dewey T, Babalaros V, Szeto WY, Williams MR, Kereiakes D, Zajarias A, Greason KL, Whitehart BK, Hodson RW, Moses JW, Trento A, Brown DL, Fearon WF, Pibarot P, Hahn RT, Jaber WA. Transcatheter or surgical aortic-valve replacement in intermediate-risk patients. N Engl J Med 2016;374:1609–1620.
4. MacL MG, Leon MB, Thourani VH, Makkar R, Kodali SK, Russo M, Kapadia SR, Malaisrie SC, Cohen DJ, Pibarot P, Leipsic J, Hahn RT, Banke P, Williams MR, McGovern JM, Brown DL, Baim DS, Rhee JS, Gorelik M, Genereux P, Pershad A, Pocock SJ, Alu MC, Webb JG, Smith CR; PARTNER 3 Investigators. Transcatheter aortic-valve replacement with a balloon-expandable valve in low-risk patients. N Engl J Med 2019;380:1695–1705.
5. Reardon MJ, Van Mieghem NM, Popma JJ, Kleiman NS, Sanderdager L, Mumentz M, Adams DH, Deeb GM, Maini B, Gada H, Chetcuti S, Glazson T, Heiser J, Jagacinski RI, Merhi W, Venet M, Piazza N, Wijns W, Cameron JS, Yakuov S, Grube E, Makkar R, Lee JS, Conte J, Xiang Y, Nguyen H, Chang Y, Mugglin AS, Serruys PWJ. Surgical or transcatheter aortic-valve replacement in intermediate-risk patients. N Engl J Med 2017;376:1321–1331.
6. Popma JJ, Deeb GM, Yakuov S, Mumentz M, Gada H, O’Hare D, Bajwa T, Heiser JC, Merhi W, Kleiman NS, Askew J, Sorajja P, Rovin J, Chetcuti S, Adams DH, Teirstein PS, Zorn GL. 3rd, Forrest JK, Tchetchel D, Resar J, Walton A, Piazza N, Lramali B, Robinson N, Petrogian G, Glazson TG, O HJ, Boulware MJ, Qiao H, Mugglin AS. Transcatheter aortic-valve replacement with a self-expanding valve in low-risk patients. N Engl J Med 2019;380:1706–1715.
7. Auffret V, Puri R, Urena M, Chamandi C, Rodriguez-Gabela T, Philippin F, Rodés-Cabau J. Conduction disturbances after transcatheter aortic valve replacement. Circulation 2017;136:1049–1069.
8. Mangieri A, Montalto C, Pagnesi M, Lanzillo G, Demir O, Testa L, Colombo A, Latala A. TAVI and post procedural cardiac conduction abnormalities. Front Cardiovasc Med 2018;5:85.
9. Lornicar F, Camara O, Pielia G, Bijnens B. Integration of artificial intelligence into clinical patient management: focus on cardiac imaging. Rev Esp Cardiol (Engl Ed) 2020;74(1);72–80.
10. Davies PR, Wang K, Mirzaz GR, Caruso A, Noble D, Walz A, Lavé T, Schuler F, Singer T, Polonchuk L. Recent developments in using mechanistic cardiac modeling for drug safety evaluation. Drug Disc Today 2016;21:524–538.
11. Corral-Acero J, Margara F, Marciniak M, Roderco C, Loncaric F, Feng Y, Gilbert A, Fernandes JF, Buhlhan HA, Wajdan A, Villegas Martinez M, Sousa Santos M, Shannanmdy M, Luo H, Westphal P, Leeson D, DiAchille P, Gurev Y, Mayr M, Gens L, Pathmanathan P, Morrison T, Cornelisens R, Prinzen D, Delhaas T, Dijkstra A, Stiges M, Vignard DJ, Zacer E, Grau V, Rodriguez B, Remme EW, Niederer S, Mortier P, McLeod K, Potse M, Puyeto E, Bueno-Orovio A, Lamata P, ‘The Digital Twin’ to enable the vision of precision cardiology. Eur Heart J 2020;41:4556–4564.
12. Roccalo G, El Faquir N, De Santis G, Iannaccione F, Bosmans J, De Backer O, Sanderdager L, Segers P, De Beule M, De Jaegere P, Mortier P. Patient-specific computer simulation to elucidate the role of contact pressure in the development of new conduction abnormalities after catheter-based implantation of a self-expanding aortic valve. Circ Cardiovasc Interp 2018;11:e00534.
13. Roccalo G, El Faquir N, De Backer O, Swaans MJ, Latalb A, Vicentin L, Segers P, De Beule M, De Jaegere P, Mortier P. The impact of size and position of a mechanical expandable transcatheter aortic valve: novel insights through computational modelling and simulation. J Cardiovasc Trans Res 2019;12;435–446.
14. Dey D, Sliomka PJ, Leeson P, Comaniciu D, Shrestha S, Sengupta PP, Marwick TH. Artificial intelligence in cardiovascular imaging: JACC state-of-the-art review. J Am Coll Cardiol 2019;73:1317–1335.
15. Bishop CM. Pattern Recognition and Machine Learning (Cambridge (UK): Springer Verlag); 2006.
16. Dowling C, Bavo AM, El Faquir N, Mortier P, De Jaegere P, De Backer O, Sanderdager L, Rulie P, Mylote J, McConhey H, Rajani R, Labourde JC, Brecker W, Gennari S, Zetti A, Meoni A, Zollo M. The 'Digital Twin' to enable the vision of precision cardiology. Eur Heart J 2020;41:4556–4564.
17. Gomes B, Pilz M, Reich FC, Luscher F, Konstandin M, Katus HA, Meder B, Latib A, TAVI and post procedural cardiac conduction abnormalities. Front Cardiovasc Med 2019;5:74.
18. Jilaihawi H, Zhao Z, Du R, Staniloea C, Saric M, Neuburger P, Querijero M, Vang E, Nguyen H, Chang Y, Arsanjani R. Machine learning helps predict permanent pacemaker requirement post transcatheter aortic valve replacement. Circulation 2019;140:A15572.
21. Truong VT, Wigle M, Bateman E, Pallerla A, NgoTam N.M., Beyerbach D, Kereiakes D, Shreenivas S, Tretter J, Palmer C, Mazur W, Chung E. Pacemaker implantation following TAVI: using machine learning to optimize risk stratification. *J Am Coll Cardiol* 2020; **75**:1478.

22. Goldstein BA, Navar AM, Carter RE. Moving beyond regression techniques in cardiovascular risk prediction: applying machine learning to address analytic challenges. *Eur Heart J* 2017; **38**:1805–1814.

23. Hamdan A, Guetta V, Klempfner R, Konen E, Raanani E, Gilison M, Goitein O, Segev A, Barbash I, Fefer P, Spiegelstein D, Goldenberg I, Schwammenthal E. Inverse relationship between membranous septal length and the risk of atrioventricular block in patients undergoing transcatheter aortic valve implantation. *JACC Cardiovasc Interv* 2015; **8**:1218–1228.

24. Siontis GCM, Juni P, Pilgrim T, Stortecky S, Büllersfeld L, Meier B, Wenaweser P, Windecker S. Predictors of permanent pacemaker implantation in patients with severe aortic stenosis undergoing TAVI. *J Am Coll Cardiol* 2014; **64**:129–140.

25. Deharo P, Bisson A, Herbert J, Lacour T, Saint Etienne C, Grammatico-Guillon L, Porto A, Collart F, Bourguignon T, Cuisset T, Fauchier L. Impact of Sapien 3 balloon-expandable versus Evolut R self-expandable transcatheter aortic valve implantation in patients with aortic stenosis: data from a nationwide analysis. *Circulation* 2020; **141**:260–268.

26. Lumens J, Tayal B, Walmley J, Delgado-Montero A, Hunjetens PR, Schwartman D, Althouse AD, Delhaas T, Prinzen FW, Gorcsan J. Differentiating electromechanical from non–electrical substrates of mechanical discoordination to identify responders to cardiac resynchronization therapy. *Circulation* 2015; **e003744**.

27. Lyon A, Ariga R, Minchakul A, Mahmoud M. Distinct ECG phenotypes identified in hypertrophic cardiomyopathy using machine learning associate with arrhythmic risk markers. *Front Physiol* 2018; **9**:213.